Publications
Detailed Information
Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Tae-Wan | - |
dc.contributor.author | Kim, Mi-Na | - |
dc.contributor.author | Kwon, Jae-Woo | - |
dc.contributor.author | Kim, Kyung-Mook | - |
dc.contributor.author | Kim, Won | - |
dc.contributor.author | Chang, Yoon-Seok | - |
dc.contributor.author | Min, Kyung-Up | - |
dc.contributor.author | Kim, You-Young | - |
dc.contributor.author | Cho, Sang-Heon | - |
dc.contributor.author | Park, Heung-Woo | - |
dc.contributor.author | Kim, Sae-Hoon | - |
dc.date.accessioned | 2012-06-27T05:51:02Z | - |
dc.date.available | 2012-06-27T05:51:02Z | - |
dc.date.issued | 2010-10 | - |
dc.identifier.citation | RESPIROLOGY; Vol.15 7; 1092-1097 | ko_KR |
dc.identifier.issn | 1323-7799 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77587 | - |
dc.description.abstract | Background and objective: Reactivation of hepatitis B virus (HBV) is thought to be associated with immunosuppressive treatments, but insufficient information is available on the effect of corticosteroids. The aim of this study was to evaluate the risk of HBV reactivation in hepatitis B surface antigen-seropositive patients with asthma or COPD, who were treated with systemic corticosteroids (SCS) in addition to inhaled corticosteroids (ICS). Methods: Patients with asthma or COPD (n = 198), who were hepatitis B surface antigen-seropositive and had been treated with ICS, were identified retrospectively. To evaluate the additional effects of SCS, the SCS group was divided into those who received intermittent or continuous SCS (>= 3 months of continuous SCS treatment), and into those who received low-dose (<= 20 mg/day of prednisolone) or medium-to-high-dose SCS. The study outcome was HBV reactivation. Results: HBV reactivation occurred in 11.1% of patients in the SCS group, which was significantly higher than the reactivation rate in the ICS group. HBV reactivation was more frequent in the SCS group compared with the ICS group (OR 3.813, 95% CI: 1.106-13.145, P = 0.032), and in the continuous and medium-to-high-dose SCS subgroups compared with the ICS group (OR 5.719, 95% CI: 1.172-27.905, P = 0.048 and OR 4.884, 95% CI: 1.362-17.511, P = 0.014, respectively). Conclusions: These results suggest that addition of SCS to ICS increases the risk of HBV reactivation, especially when SCS are administered chronically or at high doses. | ko_KR |
dc.description.sponsorship | This work was supported by a Korean Health 21
R&D Project Grant from the Ministry of Health & Welfare, Republic of Korea (A040153 & A030001). | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | WILEY-BLACKWELL | ko_KR |
dc.subject | asthma | ko_KR |
dc.subject | chronic obstructive pulmonary disease | ko_KR |
dc.subject | systemic corticosteroid | ko_KR |
dc.subject | inhaled corticosteroid | ko_KR |
dc.subject | hepatitis B virus reactivation | ko_KR |
dc.title | Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김태완 | - |
dc.contributor.AlternativeAuthor | 김미나 | - |
dc.contributor.AlternativeAuthor | 권재우 | - |
dc.contributor.AlternativeAuthor | 김경묵 | - |
dc.contributor.AlternativeAuthor | 김새훈 | - |
dc.contributor.AlternativeAuthor | 김원 | - |
dc.contributor.AlternativeAuthor | 박흥우 | - |
dc.contributor.AlternativeAuthor | 장윤석 | - |
dc.contributor.AlternativeAuthor | 조상헌 | - |
dc.contributor.AlternativeAuthor | 민경업 | - |
dc.contributor.AlternativeAuthor | 김유영 | - |
dc.identifier.doi | 10.1111/j.1440-1843.2010.01798.x | - |
dc.citation.journaltitle | RESPIROLOGY | - |
dc.description.citedreference | Koo YX, 2010, CANCER, V116, P115, DOI 10.1002/cncr.24742 | - |
dc.description.citedreference | CHO JH, 2009, KOREAN J HEPATOL, V15, P140 | - |
dc.description.citedreference | Lubel JS, 2007, INTERN MED J, V37, P705, DOI 10.1111/j.1445-5994.2007.01479.x | - |
dc.description.citedreference | Yang CH, 2007, BRIT J DERMATOL, V157, P587, DOI 10.1111/j.1365-2133.2007.08058.x | - |
dc.description.citedreference | Lalazar G, 2007, BRIT J HAEMATOL, V136, P699, DOI 10.1111/j.1365-2141.2006.06465.x | - |
dc.description.citedreference | Lok ASF, 2007, HEPATOLOGY, V45, P507, DOI 10.1002/hep.21513 | - |
dc.description.citedreference | Chou CH, 2007, CLIN CANCER RES, V13, P851, DOI 10.1158/1078-0432.CCR-06-2459 | - |
dc.description.citedreference | Thong BYH, 2007, ANN ACAD MED SINGAP, V36, P100 | - |
dc.description.citedreference | Nathan DM, 2006, J GASTROEN HEPATOL, V21, P1366, DOI 10.1111/j.1440-1746.2006.04559.x | - |
dc.description.citedreference | Lin XM, 2005, J GASTROEN HEPATOL, V20, P833, DOI 10.1111/j.1400-1746.2005.03813.x | - |
dc.description.citedreference | Esteve M, 2004, GUT, V53, P1363, DOI 10.1136/gut.2004.040675 | - |
dc.description.citedreference | Jang JW, 2004, J HEPATOL, V41, P427, DOI 10.1016/j.jhep.2004.05.014 | - |
dc.description.citedreference | Yeo W, 2004, J CLIN ONCOL, V22, P927, DOI 10.1200/JCO.2004.05.161 | - |
dc.description.citedreference | Cheng AL, 2003, HEPATOLOGY, V37, P1320, DOI 10.1053/jhep.2003.50220 | - |
dc.description.citedreference | Pauwels RA, 2003, LANCET, V361, P1071 | - |
dc.description.citedreference | Lee DH, 2002, J KOREAN MED SCI, V17, P457 | - |
dc.description.citedreference | Pedersen S, 2001, AM J RESP CRIT CARE, V164, P521 | - |
dc.description.citedreference | Perrillo RP, 2001, GASTROENTEROLOGY, V120, P1009, DOI 10.1053/gast.2001.22461 | - |
dc.description.citedreference | Szefler S, 2000, NEW ENGL J MED, V343, P1054 | - |
dc.description.citedreference | ENDO T, 2000, RINSHO KETSUEKI, V41, P322 | - |
dc.description.citedreference | Markovic S, 1999, HEPATO-GASTROENTEROL, V46, P2925 | - |
dc.description.citedreference | Agertoft L, 1998, AM J RESP CRIT CARE, V157, P178 | - |
dc.description.citedreference | Dumortier J, 1997, GASTROEN CLIN BIOL, V21, P982 | - |
dc.description.citedreference | KOGA Y, 1992, INTERNAL MED, V31, P208 | - |
dc.description.citedreference | SANDRINI S, 1990, NEPHROL DIAL TRANSPL, V5, P525 | - |
dc.description.citedreference | PARIENTE EA, 1988, DIGEST DIS SCI, V33, P1185 | - |
dc.description.citedreference | HANSON RG, 1986, HEPATOLOGY, V6, P173 | - |
dc.description.citedreference | TURKASPA R, 1986, P NATL ACAD SCI USA, V83, P1627 | - |
dc.description.citedreference | HOOFNAGLE JH, 1986, ANN INTERN MED, V104, P12 | - |
dc.description.citedreference | *GOLD, GLOB STRAT DIAGN MAN | - |
dc.description.citedreference | *GINA, GLOB STRAT ASTHM MAN | - |
dc.description.tc | 3 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.